phosphate cytidylyltransferase (PF13_0253)-also correlate with parasite survival in two other P. falciparum strains (Fig. 2B , black arrows, and table S4). The GB4 SNP alleles are shared with the NF54 and 3D7 strains that also survive, and the 7G8 SNP alleles are shared with the SL strain that is melanized by the R strain (7) . Five genes were selected as top candidates for detailed genetic analysis on the basis of large differences in gene expression and/or on polymorphisms that correlates with survival in other strains (table S5) .
Two top candidate genes, Pfs47 and Pfs48/ 45, code for members of the 6-cysteine protein family that are expressed on the gametocyte surface. Previous gene disruption experiments in the NF54 line revealed that Pfs48/45 is critical for gamete fertility (12) . Pfs47 is expressed in female gametocytes but is not essential for P. falciparum fertilization, although its homolog in Plasmodium berghei is required for female gamete fertility (12, 13) . The intensity of infection with the Pfs48/45 knockout (KO) line (NF54 genetic background) in the R strain was low, probably because of reduced fertility. However, those parasites that invaded the midgut had a similar phenotype as wild-type (WT) NF54 parasites (8) , and only 3% were melanized ( fig. S4 ), indicating that Pfs48/45 is not required to evade the mosquito immune system. In contrast, Pfs47 KO (NF54 genetic background) parasites develop and invade the midgut but are eliminated by R mosquitoes (99% melanization) (Fig. 3A) ; although Pfs47 KO parasites are not melanized by S mosquitoes (Fig. 3A) , the infection level in the S strain (median of one oocyst per midgut) is much lower than that in A. stephensi mosquitoes (60 oocysts per midgut median) ( fig. S5 ). This A. stephensi strain has been selected to be highly permissive to P. falciparum infection (14) .
To determine whether Pfs47 interacts with the mosquito immune system, we disrupted the A. gambiae complement-like system by silencing TEP1. Reducing TEP1 expression completely reversed melanization of Pfs47 KO parasites in the R strain (Fig. 3B ). In the A. gambiae S strain (G3), neither NF54 WT nor Pfs47 KO parasites were melanized (Fig. 3C) ; although TEP1 silencing had no significant effect on infection with NF54 WT parasites (Fig. 3C) , it increased both the intensity (P < 0.0001, Mann-Whitney test) and the prevalence of infection (P < 0.001; c 2 test) of Pfs47 KO parasites (Fig. 3C ). This result indicates that Pfs47 is necessary for P. falciparum parasites to evade two well-characterized immune responses mediated by TEP1 in A. gambiae: killing followed by melanization in the R strain and parasite lysis without melanization in the S strain.
Pfs47 protein is present on the surface of WT NF54 ookinetes, the stage that invades the midgut, but is absent in Pfs47 KO parasites (Fig. 3D) . The expression of HPX2 and NOX5, two enzymes that mediate midgut nitration in response to P. berghei infection and promote TEP1 activation (2), was evaluated in S mosquitoes. HPX2 and NOX5 were not induced by NF54 WT parasites, and nitration levels were lower than in uninfected controls (Fig. 3E) . In contrast, Pfs47 KO parasites induced expression of HPX2 and NOX5 and a robust nitration response, indicating that Pfs47 may prevent TEP1-mediated lysis by suppressing midgut epithelial nitration responses (Fig. 3E) .
Finally, we confirmed the importance of Pfs47 for parasite survival by complementing the Pfs47 KO line with different Pfs47 alleles (figs. S6 to S9). As expected, the NF54 allele of Pfs47 reversed the melanization phenotype (0% melanization) in the R strain when the complemented parasites were kept under sustained drug pressure, confirming that this allele of Pfs47 is sufficient to evade the immune system (Fig. 4A) . A reversal to a mixed live/melanization phenotype was observed when the drug pressure was reduced ( fig. S10 ). In contrast, complementation with the 7G8 allele failed to rescue parasites in the R strain, because 99% melanization was observed (Fig. 4B) .
Together, our findings identify Pfs47 as an essential survival factor for P. falciparum that allows the parasite to evade the immune system of A. gambiae, a major mosquito vector in Africa. However, other parasite genes may also be involved in this process. Pfs47 is a highly polymorphic gene with a marked population structure in field isolates and exhibits extreme fixation in non-African regions of the world (15, 16) . Our findings suggest that the population structure of Pfs47 may be due to adaptation of P. falciparum to the different Anopheles vector species present outside of Africa. The fact that the 7G8 allele of Pfs47 is sufficient to evade the TEP1 complementlike system in S mosquitoes but not in the R strain indicates that there are also genetic differences in the vector that determine compatibility with parasites that express specific Pfs47 alleles. It appears that Pfs47 evolved a function in P. falciparum that increases parasite survival in A. gambiae mosquitoes and may be responsible, at least in part, for the very high rates of malaria transmission in hyperendemic regions in Africa. Disruption of the immunomodulatory activity of Pfs47 may prove to be an effective strategy to reduce malaria transmission to humans. alaninemia, as well as dopamine and serotonin (5-hydroxytryptamine) deficiencies (2, 3) . The final step in BH 4 biosynthesis is the reduction of 6-pyruvoyltetrahydropterin by sepiapterin reductase (SPR) (Fig. 1A) . BH 4 is also recycled from the oxidized form of the cofactor and synthesized by a salvage pathway via dihydrobiopterin (BH 2 ) (Fig. 1A) . Recently, we showed that the anti-inflammatory drug sulfasalazine and its metabolite sulfapyridine are potent inhibitors of SPR and proposed that an inhibition of BH 4 biosynthesis by the highly permeable sulfapyridine is responsible for the anti-inflammatory activity of sulfasalazine in rheumatoid arthritis (4) . Here, we report that the inhibition of BH 4 biosynthesis contributes to the pharmacological properties of other clinically approved drugs. By screening a library of approved drugs for SPR inhibitors, we identified 10 drugs that inhibited SPR with median inhibitory concentration (IC 50 ) values below 100 nM (Fig. 1B and tables S1 and S2). These included the known SPR inhibitors sulfasalazine and sulfapyridine. Furthermore, the antibacterial sulfa drugs-sulfathiazole, sulfamethoxazole, sulfamethizole, phtalylsulfathiazole, and sulfadiazine, as well as the three antidiabetic sulfonylureas chlorpropamide, glibenclamide, and tolbutamidewere identified as potent SPR inhibitors. To gain an understanding of the binding mode of the different sulfonamides to SPR, we solved the crystal structures of SPR with bound nicotinamide adenine dinucleotide phosphate (NADP + ) and sulfapyridine or sulfathiazole. SPR, NADP + , and sulfapyridine or sulfathiazole form a ternary complex in which the sulfa drugs block the substrate binding site (Fig. 2, A and B) . The two drugs bind to SPR in a near-identical fashion (Fig. 2B) , and there are no substantial differences detectable between the two protein structures (root-mean-square deviation between backbone Ca atoms of 0.1 Å). The sulfonamide, the moiety common to all hits, and the nitrogen atom in the heteroaromatic ring of sulfapyridine and sulfathiazole form specific hydrogen bonds with active site residues Ser , Tyr
170
, and Asp 257 ( Fig.  2C) . A hydrogen bond acceptor at a position equivalent to that of the nitrogen atom in the pyridine ring of sulfapyridine is found in all identified SPR inhibitors (Fig. 1B) ; in the sulfonylureas, the oxygen atom of the urea group could function as a hydrogen bond acceptor. Previous structural studies on mouse SPR have revealed that these three residues are important for substrate binding (5) . The pyridine or thiazole rings also stack on top of the nicotinamide ring of NADP + ( Fig. 2B ) and make hydrophobic contacts with residues Leu (Fig. 1B) should be able to bind in an equivalent fashion as the heteroaromatic ring of sulfapyridine and sulfathiazole. Our structural data thus suggest how structurally diverse sulfonamides achieve inhibition of SPR but also why certain sulfa drugs, such as sulfamethazine (Fig. 1B) , are only very weak inhibitors of SPR. Sulfamethazine is a weaker inhibitor of SPR than sulfadiazine, which is 370 times as strong, although it differs from table S3 ). The listed ratio of CSF-to-blood concentration of tolbutamide was determined in rats (26, 27) . Sulfamethazine, which only weakly inhibits SPR, served as negative control throughout this work. n.a., not available. sulfadiazine only by two additional methyl groups attached to the pyrimidine ring (Fig. 1B) . A manual superimposition of sulfamethazine on sulfapyridine in the structure of SPR reveals an energetically unfavorable interaction of the two additional methyl groups with the side chains of Met 205 and Gln 206 , respectively; the distance of the sulfur atom of Met 205 and the amide nitrogen of Gln 206 to the nearest methyl group is 2.55 Å and 2.75 Å, respectively ( fig. S1, D and E) . These distances are more than 0.5 Å below the corresponding nonbonded contact distances observed in organic crystals and protein structures (6, 7) .
Next, we examined if these drugs reduce BH 4 levels in human primary dermal fibroblasts in which BH 4 biosynthesis is induced by proinflammatory cytokines. Incubation of human fibroblasts with interferon-g (IFN-g) and tumor necrosis factor-a (TNFa) for 24 hours increased BH 4 levels 165-fold to 0.33 nmol/mg protein (Fig. 3A) . SPR inhibitors decreased BH 4 levels in cytokine-stimulated fibroblasts in a dosedependent manner, whereas sulfamethazine had no effect on BH 4 levels. Dihydroneopterin triphosphate (DHNTP) is a precursor of the SPR substrate 6-pyruvoyltetrahydropterin in the biosynthesis of BH 4 (Fig. 1A) , and increased DHNTP levels have been detected in cytokine-stimulated fibroblasts derived from SPR-deficient patients (8) . Accordingly, treatment with SPR inhibitors significantly increased DHNTP levels (measured as neopterin after phosphatase treatment) ( Fig. 3A and Fig. 1A ), which confirmed that the observed decrease in BH 4 is due to an inhibition of SPR. Note that, the observed inhibition of BH 4 biosynthesis occurs at drug concentrations that are within their reported serum levels (Fig. 1B) . The exception in these experiments was sulfasalazine, which decreased BH 4 levels only at high micromolar concentrations and mainly by inhibition of cytokine signaling ( fig. S2 ). The low potency of sulfasalazine as SPR inhibitor in cell-based assays can be attributed to its low cell permeability (9). Sulfamethoxazole is currently the most-used sulfa drug and is prescribed in combination with trimethoprim (cotrimoxazole) for microbial infections and as standard treatment against Pneumocystis pneumonia (PCP), a prevalent opportunistic fungal infection in immunocompromised individuals (10, 11) . Both sulfamethoxazole and trimethoprim target pathogen tetrahydrofolate synthesis; sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, whereas trimethoprim inhibits dihydrofolate reductase (DHFR). Adverse effects of sulfamethoxazoletrimethoprim at standard dose for bacterial infection are relatively rare, but CNS-related side effects are frequently observed at the higher therapeutic dose used in PCP (up to 100 mg/kg of body weight per day sulfamethoxazole and 20 mg/kg per day of trimethoprim). These include anorexia, nausea, headache, nervousness, fine tremors, lightheadedness, insomnia, and drowsiness (see table S4 for a compilation of reports concerning CNS-related adverse effects). For example, administering 100 mg/kg per day of sulfamethoxazole to 12 healthy adults resulted in CNS-related adverse effects in all subjects within 3 days (12) . Furthermore, recent analyses of clinical data of PCP patients indicate that highdose sulfamethoxazole-trimethoprim therapy can cause psychosis; the reported incidence being 12 to 20% (13, 14) . Nausea, vomiting, and CNSrelated symptoms are common, dose-dependent adverse effects of most sulfa drugs (15) (16) (17) . In sulfasalazine treatment, these symptoms are correlated with serum concentrations of sulfapyridine but not sulfasalazine (18) . In dogs, which exhibit CNS-related side effects similar to those of humans (19) , complete gastrointestinal evisceration or direct application of sulfapyridine to the vomiting center showed that nausea and vomiting are not caused by direct action of the drug on the gastrointestinal tract or the vomiting center (20) . The inhibition of BH 4 biosynthesis by sulfa drugs and a subsequent inhibition of neurotransmitter biosynthesis could provide a rationale for their CNS-related side effects. This hypothesis is supported by the observation that the adverse effects of sulfamethoxazole resemble the symptoms of genetically inherited SPR deficiency. Basal levels of BH 4 in SPR deficiency in most tissues are maintained through salvage or alternative pathways (Fig. 1A ). An exception is the brain, where the low expression level of the enzymes involved in salvage pathways, such as DHFR, diminishes their efficiency. Symptoms of SPR deficiency are those of catecholamine and serotonin deficiencies with disabling motor and cognitive deficits (2) . Furthermore, recurrent vomiting is a gastrointestinal symptom of SPR deficiency (2) . SPR deficiency can be most reliably diagnosed through analysis of cerebrospinal fluid (CSF); CSF concentrations of BH 2 and sepiapterin in SPR deficiency are significantly increased whereas those of dopamine and serotonin metabolites are decreased (2) . An effect of sulfamethoxazole-trimethoprim on biopterin levels in CSF has been reported previously: Patients with Machado-Joseph disease, an autosomal dominantly inherited neurodegenerative disorder, who were administered sulfamethoxazoletrimethoprim (400 mg sulfamethoxazole, 80 mg trimethoprim, twice daily) showed significantly increased BH 2 levels in CSF (21) . Dopamine insufficiency has been reported in a child with dihydropteridine reductase (DHPR) deficiency after being given sulfamethoxazole-trimethoprim (22) . DHPR is involved in recycling of BH 4 (Fig. 1A) , and the observed dopamine insufficiency could be explained by a further depletion of already decreased BH 4 levels through inhibition of SPR.
To demonstrate that sulfa drugs can lower neurotransmitter levels through depletion of BH 4 , we investigated whether sulfa drugs in cell culture experiments would affect catecholamine biosynthesis in the human neuroblastoma cell line SK-N-BE (2) (23). SK-N-BE(2) cells have constitutively high levels of BH 4 and excrete substantial amounts of the dopamine metabolite 3-methoxytyramine (3-MT). The identified SPR inhibitors, with the exception of sulfasalazine, at 200 mM, decreased intracellular BH 4 and extracellular 3-MT levels (Fig. 3B) . The activities in this cellular assay, again with the exception of sulfasalazine, correlated well with the IC 50 values measured in the enzymatic assay (Figs. 1B and  3B ). For more detailed analysis, SK-N-BE(2) cells were incubated with varying concentrations of sulfathiazole, sulfamethoxazole, or sulfapyridine; the drugs decreased BH 4 levels from 0.3 to 0.05 nmol/mg protein, with IC 50 values of 23, 59, and 201 mM, respectively (Fig. 3C) . To examine tyrosine hydroxylase activity in drug-treated cells, extracellular L-dopa levels were measured after 24 hours of treatment with sulfathiazole, sulfamethoxazole, or sulfapyridine ( Fig. 3C) (24) . In these experiments, sulfamethoxazole, sulfathiazole, and sulfapyridine decreased L-dopa levels with IC 50 values of 31, 63, and 143 mM, respectively. In conclusion, sulfa drugs at concentrations below their serum levels interfere with catecholamine biosynthesis through BH 4 depletion. We assume that similar effects will be observed on serotonin biosynthesis.
Our findings, together with ample clinical observations, suggest that inhibition of BH 4 biosynthesis by sulfa drugs is responsible for some of their CNS-related side effects. The incidence of these side effects will depend on the inhibitory activity of the sulfa drug toward SPR-its serum concentration during therapy, as well as its uptake into the CNS. Sulfamethoxazole reaches plasma levels of up to 600 mM, shows good uptake into the CNS, and is a potent inhibitor of SPR in cellular assays (Fig. 1B and Fig. 3) ; we therefore conclude that sulfamethoxazole at these doses will affect BH 4 and catecholamine biosynthesis in the brain. The excellent CNS uptake of sulfapyridine and its good inhibitory activity against SPR explain why its CNS-related side effects are already observed at lower serum concentrations compared with other sulfa drugs also inhibiting SPR (i.e., sulfadiazine). Furthermore, sulfa drugs not inhibiting SPR also show diminished CNSrelated side effects. In early studies on the efficacy of sulfamethazine in treatment of labor pneumonia (73 patients), it was noted that "The striking difference, however, was that the patients never complained of the severe mental and physical depression which often accompanies sulfapyridine treatment" (25) . CNS-related side effects have not been published for first-generation sulfonylureas tolbutamide and chlorpropamide and second-generation sulfonylurea glibenclamide. The effective serum concentration of glibenclamide is too low for SPR inhibition (Fig. 1B) . However, the serum concentrations of tolbutamide and chlorpropamide are comparable to those measured for sulfa drugs. We assume that low CNS uptake of these drugs is responsible for the absence of such side effects. In fact, tolbutamide uptake in rat CNS is extremely low compared with other drugs (26, 27) .
Sulfa drugs were the scaffold for the development of multiple other drugs (28) . Proteins that are targeted by such drugs-for example, carbonic anhydrase and endothelin receptor-are therefore possible off-targets of sulfa drugs, and some carbonic anhydrase inhibitors (sultiame) or endothelin receptor antagonists (sitaxentan) cause side effects such as headache and dizziness. We could not observe inhibition of human carbonic anhydrase II, a representative isozyme of carbonic anhydrases, by sulfa drugs (IC 50 > 1 mM in an enzymatic assay) (table S6). Sulfamethoxazole and sulfathiazole were reported to compete with endothelin-1 for binding to endothelin receptor type A with IC 50 values that are within their therapeutic serum concentrations, but in functional assays sulfamethoxazole did not show activity at the highest concentrations tested (100 mM) (table S7). These observations allow us to rule out carbonic anhydrase II but not endothelin receptor as potential additional off-targets. More generally speaking, our results do not exclude the presence of other off-targets of sulfa drugs.
Our finding that sulfa drugs interfere with BH 4 -dependent neurotransmitter biosynthesis also suggests strategies for a potential improvement of PCP therapy. L-Dopa or 5-hydroxytryptophan, which are successfully used as supplements in SPR deficiency (2) , might dampen some of their CNS-related side effects in high-dose sulfamethoxazole therapy. Second, sulfa drugs displaying no, or weak, SPR inhibition should be considered as alternatives to sulfamethoxazole (29) . In summary, the identification of sulfa drugs as inhibitors of BH 4 biosynthesis is of relevance for understanding the history of sulfa drugs and has direct implications for their future use. Cell-cell and cell-matrix mechanical interactions through membrane receptors direct a wide range of cellular functions and orchestrate the development of multicellular organisms. To define the single molecular forces required to activate signaling through a ligand-receptor bond, we developed the tension gauge tether (TGT) approach in which the ligand is immobilized to a surface through a rupturable tether before receptor engagement. TGT serves as an autonomous gauge to restrict the receptor-ligand tension. Using a range of tethers with tunable tension tolerances, we show that cells apply a universal peak tension of about 40 piconewtons (pN) to single integrin-ligand bonds during initial adhesion. We find that less than 12 pN is required to activate Notch receptors. TGT can also provide a defined molecular mechanical cue to regulate cellular functions.
C ells sense and respond to the mechanical properties of the surrounding extracellular matrix (ECM) and neighboring cells. Reciprocally, cells also apply force on the ECM and transmit mechanical signals to neighboring cells. These mechanical interactions activate intracellular signaling pathways and regulate such diverse processes as cell adhesion, polarization, migration, proliferation, and differentiation (1, 2). As a result, by tuning bulk mechanical properties like stiffness, texture, and geometry of the substrate, researchers have gained insight into processes such as stem cell differentiation (3) and tumor metastasis (4) . Single-molecule force spectroscopy has been used to study various mechanosensitive membrane receptors, including integrin, cadherin, and Notch (5-8). However, these approaches cannot reveal the single-molecule forces required for physiological functions because they either measure collective forces exerted through many molecules or probe molecular unbinding or unfolding forces only. More recently, fluorescence resonance energy transfer-based force sensors were developed and inserted to target sites to monitor cellular forces (9, 10), but great efforts must be taken to prepare the sensors and to track and interpret the fluorescence signal. Here, we describe a platform termed tension gauge tether (TGT) that allows us to determine the single-molecule forces required for mechanical signaling in cells.
In TGT, a ligand is covalently conjugated to a tether that ruptures at a critical force, which we term "tension tolerance" or T tol , and is immobilized on a solid surface through the tether (Fig. 1) . Cells are plated on the surface, and membrane receptors engage with and apply tension to the ligands. If signal activation through the receptor requires a molecular tension larger than T tol , the tether will rupture, abolishing signal activation. In contrast, if the required tension is smaller than T tol , the tether will endure, activating the receptor-mediated signaling. By engineering a series of tethers with different T tol values, the tension required for signal activation can be determined by observing receptor-regulated cell activities, which are usually much easier to detect than single-molecule events. Because each ligand is equipped with an individual tension gauge, the measurement is independent of the receptor or ligand density.
DNA is a good candidate for use as rupturable tether in TGT because force application geometry ( fig. S1 ) strongly affects its rupture force, with an unzipping force rupturing the DNA at a much lower force than a shearing force (11, 12) . Albrecht et al. have exploited this feature to estimate the rupture force of an antigen-antibody bond relative to the rupture forces of double-stranded DNA (dsDNA) in unzipping or shear geometry (13) . The estimated rupture force of a 21-base pair (bp) DNA is about 12 pN in the unzipping geometry and is about 56 pN in the shear geometry (14) . Intermediate rupture forces can be obtained by applying forces through an internal position on the DNA duplex, and the theoretical T tol values of the resulting tethers can be estimated (Fig. 1D and fig. S2 ). T tol represents the force required to rupture the tether in less than 2 s when the force is applied at a constant level (12) [see supplementary text (14) ].
Integrins are membrane receptors that mediate cell adhesion and sense and transduce mechanical information from the ECM into cells. Bulk traction forces applied through a collection of integrin-ligand bonds have been extensively examined (15) (16) (17) (18) . Here, we apply the TGT platform to probe the tension on a single integrin-ECM ligand bond required for cell adhesion (specifically, integrin a V b 3 and its ligand, cyclic RGDfK peptide). To reduce nonspecific adhesion, ligands with the DNA tether are immobilized through an Avidin-biotin linker on a glass surface passivated with polyethylene glycol (PEG). The Avidinbiotin unbinding force,~160 pN (19) , is much larger than the tether rupture forces used here (≤56 pN).
We conjugated RGDfK to nine different DNA tethers with estimated T tol values of 12, 16, 23, 33, 43, 50, 54, 55, and 56 pN ( fig. S2 ). These DNA tethers have various force application geometries but share the same length, sequence, and thermal stability. ATGT array was created by
